Loading stock data…
Croda International Plc engages in the consumer care (CRDA.L)
LSE3,327pGBX+64.00p (+1.96%)
Market ClosedLast close Sep 8
Croda International Plc engages in the consumer care, life science, and industrial specialty businesses in Europe, the Middle East, Africa, North America, Asia, and Latin America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CRDA.L in the Basic Materials sector is trading at 3,327p. Wall Street consensus targets 3,673p (13 analysts), implying a +10.4% move over the next 12 months. The stock is currently near its 52-week high of 3,520p, remaining 13.6% above its 200-day moving average. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +10.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (GBP) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | £2.09B↑ | £1.69B↑ | £1.63B↓ | £1.70B |
| Gross Profit | £985.60M↑ | £730.00M↓ | £733.90M↓ | £745.70M |
| Operating Income | £444.70M↑ | £247.50M↑ | £242.50M↓ | £259.60M |
| Net Income | £649.30M↑ | £171.00M↑ | £158.50M↑ | £62.00M |
Peer Comparison
Fundamentals
Croda International Plc engages in the consumer care, life science, and industrial specialty businesses in Europe, the Middle East, Africa, North America, Asia, and Latin America. The company offers consumer care products across beauty care, beauty a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
57.16
Beta
Defensive asset. Lower volatility than the S&P 500.
0.92
Div Yield
Strong income play. Yield provides a meaningful total return floor.
338.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.68%
Volume
Today's trading volume
7,293
Recent News
Croda International H1 Earnings Call Highlights
Croda International (LON:CRDA) said its first-half results met expectations as growth accelerated in the second quarter, supported by Consumer Care and a strong performance in Beauty Actives. The company maintained its full-year 2026 outlook and said its transformation program was producing savings
How An Unchanged Valuation Is Shaping The Evolving Story At Croda International (LSE:CRDA)
Croda International’s latest analyst update comes with a clear signal, as price targets remain unchanged despite fresh review. With no revisions to those targets, you are getting a clean snapshot of how the stock currently lines up against existing expectations, without any extra noise. Read on to see how to track these kinds of updates and keep on top of the evolving narrative around Croda International. Analyst Price Targets don't always capture the full story. Head over to our Company...
UK Stocks Estimated To Be Trading Below Fair Value In May 2026
The UK stock market has been experiencing turbulence, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic challenges. Amidst these fluctuations, identifying undervalued stocks can offer potential opportunities for investors looking to capitalize on discrepancies between a company's market price and its intrinsic value.
3 UK Stocks Possibly Trading Below Fair Value Estimates In April 2026
As the UK market grapples with global economic challenges, including weak trade data from China impacting the FTSE 100, investors are keenly observing potential opportunities amidst these fluctuations. In this environment, identifying stocks that may be trading below their fair value can offer a strategic advantage for those looking to navigate the current uncertainties effectively.
Croda International Q1 Earnings Call Highlights
Croda International (LON:CRDA) reported first-quarter 2026 sales growth broadly in line with expectations and reiterated its full-year outlook, with management saying the Middle East conflict had no material impact on Q1 results despite increasing input cost pressures. Q1 sales performance and guid